Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer

Sembulingam Tamilzhalagan; Muthulakshmi Muthuswami; Jayaprakash Periasamy; Ming Hui Lee; Sun Young Rha; Patrick Tan; Kumaresan Ganesan

doi:10.1016/j.cellsig.2015.02.010

Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer

Sembulingam Tamilzhalagan, Muthulakshmi Muthuswami, Jayaprakash Periasamy, Ming Hui Lee, Sun Young Rha, Patrick Tan, Kumaresan Ganesan

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Chromosomal aberrations are hallmarks of cancers and the locus of frequent genomic amplifications often harbors key cancer driver genes. Many genomic amplicons remain larger with hundreds of genes and the key drivers remain to be identified by an amplification-wide systematic analysis. The 7q21.12-q22.3 genomic amplification is frequent in gastric cancers which occur in ~. 10% of the patients and multiple cell lines. This 7q21.12-q22.3 amplicon has not yet been completely analyzed towards identifying the driver genes and their functional contribution in oncogenesis. The amplitude and prevalence indicate the important role conferred by this amplicon in gastric cancers. Among the 159 genes of this amplicon, 12 genes are found over-expressed in primary gastric tumors and cell lines. Many of the over-expressed genes show negative association with p53 transcriptional activity. RNAi based functional screening of the genes reveal, SHFM1 as key gastric cancer driver gene. SHFM1 confers cell cycle progression and resistance to p53 stabilizing drugs in gastric cancer cells. SHFM1 also activates Src, MAPK/ERK and PI3K/Akt signaling pathways. This is the first integrative genomic investigation of 7q21.12-q22.3 amplicon revealing the potential oncogenic candidacy of 12 genes. The oncogenic contribution of SHFM1, mediated by the p53 suppressive feature has been demonstrated in gastric cancer cells.

Original language	English
Pages (from-to)	1075-1086
Number of pages	12
Journal	Cellular Signalling
Volume	27
Issue number	6
DOIs	https://doi.org/10.1016/j.cellsig.2015.02.010
Publication status	Published - 2015 Jun 1

Bibliographical note

Funding Information:
This project was funded by Department of Biotechnology (DBT), Govt. of India through the RNAi task force research grant BT/PR12893/AGR/36/628/2009 to Kumaresan Ganesan, Madurai Kamaraj University. NET-UGC fellowship support to Sembulingam Tamilzhalagan and DST-INSPIRE fellowship to Muthulakshmi Muthuswami are acknowledged. Instrumentation supports of UGC-CEGS, DBT-IPLS, UGC-NRCBS, UGC-CAS, and DST-PURSE programme supported central facilities of SBS, MKU are acknowledged. Our sincere thanks to Dr. Suresh Kumar Rayala, IIT Madras for his support with Akt, MAPK/ERK1/2 antibodies. Authors thank Ms. M. Niraimathi and Dr. A. Mahesh for technical support at MKU-HCS and MKU-FACS facility. We thank the TCGA research network for the accessibility of data.

Publisher Copyright:
© 2015 Elsevier Inc.

All Science Journal Classification (ASJC) codes

Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cellsig.2015.02.010

Cite this

@article{31caf1ce963d4c16bf61006f8d32326d,

title = "Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer",

abstract = "Chromosomal aberrations are hallmarks of cancers and the locus of frequent genomic amplifications often harbors key cancer driver genes. Many genomic amplicons remain larger with hundreds of genes and the key drivers remain to be identified by an amplification-wide systematic analysis. The 7q21.12-q22.3 genomic amplification is frequent in gastric cancers which occur in ~. 10% of the patients and multiple cell lines. This 7q21.12-q22.3 amplicon has not yet been completely analyzed towards identifying the driver genes and their functional contribution in oncogenesis. The amplitude and prevalence indicate the important role conferred by this amplicon in gastric cancers. Among the 159 genes of this amplicon, 12 genes are found over-expressed in primary gastric tumors and cell lines. Many of the over-expressed genes show negative association with p53 transcriptional activity. RNAi based functional screening of the genes reveal, SHFM1 as key gastric cancer driver gene. SHFM1 confers cell cycle progression and resistance to p53 stabilizing drugs in gastric cancer cells. SHFM1 also activates Src, MAPK/ERK and PI3K/Akt signaling pathways. This is the first integrative genomic investigation of 7q21.12-q22.3 amplicon revealing the potential oncogenic candidacy of 12 genes. The oncogenic contribution of SHFM1, mediated by the p53 suppressive feature has been demonstrated in gastric cancer cells.",

author = "Sembulingam Tamilzhalagan and Muthulakshmi Muthuswami and Jayaprakash Periasamy and Lee, {Ming Hui} and Rha, {Sun Young} and Patrick Tan and Kumaresan Ganesan",

note = "Funding Information: This project was funded by Department of Biotechnology (DBT), Govt. of India through the RNAi task force research grant BT/PR12893/AGR/36/628/2009 to Kumaresan Ganesan, Madurai Kamaraj University. NET-UGC fellowship support to Sembulingam Tamilzhalagan and DST-INSPIRE fellowship to Muthulakshmi Muthuswami are acknowledged. Instrumentation supports of UGC-CEGS, DBT-IPLS, UGC-NRCBS, UGC-CAS, and DST-PURSE programme supported central facilities of SBS, MKU are acknowledged. Our sincere thanks to Dr. Suresh Kumar Rayala, IIT Madras for his support with Akt, MAPK/ERK1/2 antibodies. Authors thank Ms. M. Niraimathi and Dr. A. Mahesh for technical support at MKU-HCS and MKU-FACS facility. We thank the TCGA research network for the accessibility of data. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.cellsig.2015.02.010",

language = "English",

volume = "27",

pages = "1075--1086",

journal = "Cellular Signalling",

issn = "0898-6568",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer

AU - Tamilzhalagan, Sembulingam

AU - Muthuswami, Muthulakshmi

AU - Periasamy, Jayaprakash

AU - Lee, Ming Hui

AU - Rha, Sun Young

AU - Tan, Patrick

AU - Ganesan, Kumaresan

N1 - Funding Information: This project was funded by Department of Biotechnology (DBT), Govt. of India through the RNAi task force research grant BT/PR12893/AGR/36/628/2009 to Kumaresan Ganesan, Madurai Kamaraj University. NET-UGC fellowship support to Sembulingam Tamilzhalagan and DST-INSPIRE fellowship to Muthulakshmi Muthuswami are acknowledged. Instrumentation supports of UGC-CEGS, DBT-IPLS, UGC-NRCBS, UGC-CAS, and DST-PURSE programme supported central facilities of SBS, MKU are acknowledged. Our sincere thanks to Dr. Suresh Kumar Rayala, IIT Madras for his support with Akt, MAPK/ERK1/2 antibodies. Authors thank Ms. M. Niraimathi and Dr. A. Mahesh for technical support at MKU-HCS and MKU-FACS facility. We thank the TCGA research network for the accessibility of data. Publisher Copyright: © 2015 Elsevier Inc.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Chromosomal aberrations are hallmarks of cancers and the locus of frequent genomic amplifications often harbors key cancer driver genes. Many genomic amplicons remain larger with hundreds of genes and the key drivers remain to be identified by an amplification-wide systematic analysis. The 7q21.12-q22.3 genomic amplification is frequent in gastric cancers which occur in ~. 10% of the patients and multiple cell lines. This 7q21.12-q22.3 amplicon has not yet been completely analyzed towards identifying the driver genes and their functional contribution in oncogenesis. The amplitude and prevalence indicate the important role conferred by this amplicon in gastric cancers. Among the 159 genes of this amplicon, 12 genes are found over-expressed in primary gastric tumors and cell lines. Many of the over-expressed genes show negative association with p53 transcriptional activity. RNAi based functional screening of the genes reveal, SHFM1 as key gastric cancer driver gene. SHFM1 confers cell cycle progression and resistance to p53 stabilizing drugs in gastric cancer cells. SHFM1 also activates Src, MAPK/ERK and PI3K/Akt signaling pathways. This is the first integrative genomic investigation of 7q21.12-q22.3 amplicon revealing the potential oncogenic candidacy of 12 genes. The oncogenic contribution of SHFM1, mediated by the p53 suppressive feature has been demonstrated in gastric cancer cells.

AB - Chromosomal aberrations are hallmarks of cancers and the locus of frequent genomic amplifications often harbors key cancer driver genes. Many genomic amplicons remain larger with hundreds of genes and the key drivers remain to be identified by an amplification-wide systematic analysis. The 7q21.12-q22.3 genomic amplification is frequent in gastric cancers which occur in ~. 10% of the patients and multiple cell lines. This 7q21.12-q22.3 amplicon has not yet been completely analyzed towards identifying the driver genes and their functional contribution in oncogenesis. The amplitude and prevalence indicate the important role conferred by this amplicon in gastric cancers. Among the 159 genes of this amplicon, 12 genes are found over-expressed in primary gastric tumors and cell lines. Many of the over-expressed genes show negative association with p53 transcriptional activity. RNAi based functional screening of the genes reveal, SHFM1 as key gastric cancer driver gene. SHFM1 confers cell cycle progression and resistance to p53 stabilizing drugs in gastric cancer cells. SHFM1 also activates Src, MAPK/ERK and PI3K/Akt signaling pathways. This is the first integrative genomic investigation of 7q21.12-q22.3 amplicon revealing the potential oncogenic candidacy of 12 genes. The oncogenic contribution of SHFM1, mediated by the p53 suppressive feature has been demonstrated in gastric cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=84939972327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939972327&partnerID=8YFLogxK

U2 - 10.1016/j.cellsig.2015.02.010

DO - 10.1016/j.cellsig.2015.02.010

M3 - Article

C2 - 25697906

AN - SCOPUS:84939972327

SN - 0898-6568

VL - 27

SP - 1075

EP - 1086

JO - Cellular Signalling

JF - Cellular Signalling

IS - 6

ER -

Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this